246 related articles for article (PubMed ID: 34124243)
1. Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes.
Arrigo A; Saladino A; Aragona E; Mercuri S; Introini U; Bandello F; Parodi MB
Biomed Res Int; 2021; 2021():5516981. PubMed ID: 34124243
[TBL] [Abstract][Full Text] [Related]
2. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections.
Rasmussen A; Sander B; Larsen M; Brandi S; Fuchs J; Hansen LH; Lund-Andersen H
Acta Ophthalmol; 2017 Mar; 95(2):128-132. PubMed ID: 27535819
[TBL] [Abstract][Full Text] [Related]
3. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
Kaya F
J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
[TBL] [Abstract][Full Text] [Related]
4. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study.
Kim JH; Lee DW; Chang YS; Kim JW; Kim CG
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2101-2109. PubMed ID: 27230919
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G
Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.
Matsumoto H; Hiroe T; Morimoto M; Mimura K; Ito A; Akiyama H
Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171
[TBL] [Abstract][Full Text] [Related]
7. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
8. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
9. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
10. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
[TBL] [Abstract][Full Text] [Related]
11. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
[TBL] [Abstract][Full Text] [Related]
12. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
Nguyen CL; Oh LJ; Wong E; Wei J; Chilov M
BMC Ophthalmol; 2018 May; 18(1):130. PubMed ID: 29843663
[TBL] [Abstract][Full Text] [Related]
14. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
15. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
[TBL] [Abstract][Full Text] [Related]
16. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
Braimah IZ; Agarwal K; Mansour A; Chhablani J;
Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
[TBL] [Abstract][Full Text] [Related]
17. Subfoveal Choroidal Thickness in Eyes with Neovascular Age-Related Macular Degeneration Treated with Anti-Vascular Endothelial Growth Factor Agents.
Kanadani TCM; Veloso CE; Nehemy MB
Ophthalmologica; 2018; 240(4):200-207. PubMed ID: 29768266
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of treat-and-extend versus pro re nata regimens in the treatment of Neovascular Age Macular Degeneration: A Real World Comparison.
Meira J; Carneiro J; Madeira C; Falcão M; Beato J; Correia S; Falcão-Reis F; Carneiro Â
Arch Soc Esp Oftalmol (Engl Ed); 2020 Jun; 95(6):263-270. PubMed ID: 32370878
[TBL] [Abstract][Full Text] [Related]
19. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.
Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V
J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059
[TBL] [Abstract][Full Text] [Related]
20. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]